ACLX - Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market
2024-06-26 11:19:28 ET
Summary
- Arcellx is advancing Anito-cel in a pivotal Phase 2 trial for relapsed or refractory multiple myeloma, showing promising early results.
- Anito-cel has demonstrated a 100% overall response rate and a 76% complete response rate in early trials.
- The collaboration with Kite enhances Arcellx's operational capabilities and financial stability, supporting the development of Anito-cel.
- I recommend continuing to buy ACLX stock based on promising early clinical data and strategic partnerships.
Arcellx’s Anito-cel: A Promising Contender in Multiple Myeloma Therapy
Arcellx ( ACLX ) is developing cell therapies for multiple myeloma [MM], acute myeloid leukemia, and myelodysplastic syndrome. Anito-cel (formerly CART-ddBCMA), the company's flagship product, is being developed in a Phase 2 pivotal trial for relapsed or refractory MM (rrMM). My last article on Arcellx was in September, a month after the FDA lifted the partial clinical hold (limits some trial aspects) on their T-cell therapy for rrMM, Anito-cel. The partial hold came after a patient died in the pivotal Phase 2 iMMagine-1 clinical trial. The death was reportedly and unfortunately due to a deviation in trial protocol that treated a patient who should have been ineligible. I concluded that their efforts in rrMM are "potentially groundbreaking" and recommended a speculative buy on ACLX. Its stock is up 45% since the recommendation, while the S&P 500 is up 22%....
Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market